Isatuximab-Specific Immunofixation Electrophoresis Assay to Remove Interference in Serum M-Protein Measurement in Patients with Multiple Myeloma
The Journal of Applied Laboratory Medicine · 2024
DOI: 10.1093/jalm/jfae028 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Applied Laboratory Medicine, 2024. Verfasst von Katie Thoren und 3 weiteren Autor:innen. Beteiligte Einrichtung: Memorial Sloan Kettering Cancer Center, New York, NY, United States. Hauptthemen laut MEDLINE: Multiple Myeloma, Immunoelectrophoresis, Myeloma Proteins, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Isatuximab, an IgG-kappa (IgGκ) anti-cluster of differentiation 38 (CD38) monoclonal antibody approved for use in patients with relapsed or refractory multiple myeloma (MM), can potentially interfere with the visualization of endogenous monoclonal protein (M-protein) on standard immunofixation electrophoresis (IFE) and lead to inaccurate classification of a patient’s response to therapy. The Hydrashift 2/4 isatuximab IFE assay (Hydrashift isatuximab assay) removes isatuximab interference from IFE. Using samples from patients enrolled in clinical trials of isatuximab-based therapy for MM, we demonstrate how the Hydrashift isatuximab assay improves the ability to detect residual M-protein and offer recommendations for when the assay is most useful.
Methods
Samples from 141 patients with a variety of known M-protein isotypes were selected and analyzed by standard IFE and the Hydrashift isatuximab assay. A positive control containing isatuximab was run on every standard IFE and Hydrashift gel.
Results
The Hydrashift isatuximab assay reliably shifted the migration of isatuximab in patient samples. Standard IFE was adequate for determining 104 patients’ M-protein status, and the Hydrashift isatuximab assay confirmed these results. In samples from 37 patients with a history of IgGκ MM and a single IgGκ band visible on standard IFE near the isatuximab migration site, the Hydrashift isatuximab assay was able to separate isatuximab from endogenous M-protein, identifying residual M-protein in 17 samples and preventing false-positive interpretations of standard IFE in 20 samples.
Conclusions
The Hydrashift isatuximab assay is most useful in patients with known IgGκ MM when a single IgGκ band appears near the isatuximab migration site on standard IFE during isatuximab-based therapy. ClinicalTrials.gov Registration Numbers NCT03275285 and NCT03319667.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Memorial Sloan Kettering Cancer Center, New York, NY, United States.
- Sebia, Lisses, France.
- Sanofi R&D, Chilly-Mazarin, France.
Zitieren
APA
Thoren, K., Menad, S., Nouadje, G., & Macé, S. (2024). Isatuximab-Specific Immunofixation Electrophoresis Assay to Remove Interference in Serum M-Protein Measurement in Patients with Multiple Myeloma. The Journal of Applied Laboratory Medicine. https://doi.org/10.1093/jalm/jfae028
Vancouver
Thoren K, Menad S, Nouadje G, Macé S. Isatuximab-Specific Immunofixation Electrophoresis Assay to Remove Interference in Serum M-Protein Measurement in Patients with Multiple Myeloma. The Journal of Applied Laboratory Medicine. 2024. doi:10.1093/jalm/jfae028
BibTeX
@article{Thoren2024,
author = {Thoren, Katie and Menad, Samia and Nouadje, Georges and Macé, Sandrine},
title = {Isatuximab-Specific Immunofixation Electrophoresis Assay to Remove Interference in Serum M-Protein Measurement in Patients with Multiple Myeloma},
journal = {The Journal of Applied Laboratory Medicine},
year = {2024},
doi = {10.1093/jalm/jfae028}
}
EUVIMED